[Current Status and Future Direction of Cancer Genomic Medicine in Japan].

From June, 2019, 2 different cancer genomic profiling(CGP)test panels(OncoguideNCCOncopanel, FoundationOneCDx) were decided to be covered by National Insurance System in Japan. To run the precision medicine based on CGP(genomic medicine), Ministry of Health, Labour and Welfare of Japan assigned the 11 certified core hospitals on genomic medicine, 34 sub-core hospitals and affiliated hospitals. In addition, Center for Cancer Genomics and Advanced Therapeutics(C-CAT) was established to collect genomic data and clinical data from these hospitals in June, 2018. To reimburse the genomic medicine, so called "expert-panel" with sufficient required specialists(eg medical oncologist, pathologist, genomic counselor, bioinformatician, et al)must be held to discuss on the treatment strategy and secondary findings. The expert panel was held by certified core hospital for genomic medicine and their affiliated hospital should join it. One of the important problems is the availability for drug based on genomic panel. In real world, only 10-15%of the patients can access the drug as a clinical trial. Secondary findings are also important issue to manage. To improve the operation and management of genomic medicine in clinical practice, we have to solve these issues as soon as possible.